Antimigraine drugs are medications intended to reduce the effects or intensity of migraine headache. They include drugs for the treatment of acute migraine symptoms as well as drugs for the prevention of migraine attacks. Treatment of acute symptoms Examples of specific antimigraine drug classes include triptans (first line option), ergot alkaloids, ditans and gepants. Migraines can also be treated with unspecific analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen. Opioids are not recommended for treatment of migraines. Triptans The triptan drug class includes 1st generation sumatriptan (which has poor bioavailability), and second generation zolmitriptan. Due to their safety, efficacy and selectivity, triptans are considered first line agents for abortion of migraines. These medications are selective 5-HT1B/1D receptor agonists with some activity at 5-HT1F. They produce an antimigraine effect by vasoconstriction of the vessels in the brain, as well as inhibiting trigeminal CGRP release and pain transmission. They are normally well tolerated but the vasoconstrictor effects can lead to problematic side effects such as nausea, dizziness and chest discomfort, and therefore require caution in patients with cardiovascular disease. There is also an increased risk of gastrointestinal adverse events. Triptans use is limited to less than ten times per month in order to reduce Medication Overuse Headache (MOH). Ergots alkaloids Ergot alkaloids include ergotamine and dihydroergotamine. This medication class targets the GCRP receptor pathway due to their likeness to serotonin, dopamine and noradrenaline. They show activity at serotonin 5-HT1-2, dopamine D2-like and alpha1/alpha2-adrenoreceptors. Their lack of selectivity leads to more adverse effects, making them second line compared to triptans. However, they have been shown to prevent recurrence better than triptans. Adverse effects include nausea, vomiting, paresthesia, and ergotism. Their use is limited to less than ten times per month in order to reduce medication overuse headaches (MOH's). The oral dosage administrative form is considered less effective than nasal or parenteral forms and has been discontinued in Canada. Ergotamine is contraindicated during pregnancy. Ditans Ditans (eg. lasmiditan) are a new group of anti migraine drugs which were developed due some of the concerns with the 1st line triptans (eg. adverse effects, concern with use in cardiovascular disease, use of less than 10x per month to reduce MOH). Ditans are 5-HT1F receptors agonists. Lasmiditan has been suggested to have less pain relief when compared to the triptans at the 2 hour mark post taking the medication. Lasmitan was shown to have higher adverse